{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:19:31Z","timestamp":1789348771465,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.berh.2020.101486","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T18:01:30Z","timestamp":1581616890000},"page":"101486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pitfalls in the diagnosis of myositis"],"prefix":"10.1016","volume":"34","author":[{"given":"Hector","family":"Chinoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Lilleker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.berh.2020.101486_bib1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for adult and Juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2020.101486_bib2","article-title":"Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study","volume":"2","author":"Parker","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.berh.2020.101486_bib3","series-title":"Neuromuscular disorders","article-title":"224th ENMC International Workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort","author":"Allenbach","year":"2018"},{"key":"10.1016\/j.berh.2020.101486_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"10.1016\/j.berh.2020.101486_bib5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.berh.2019.03.012","article-title":"Myositis in clinical practice\u2014relevance of new antibodies","volume":"32","author":"Moghadam-Kia","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2020.101486_bib6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2020.101486_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/rheumatology\/key343","article-title":"The performance of the European League against Rheumatism\/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort","volume":"58","author":"Parker","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2020.101486_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","article-title":"EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia","volume":"17","author":"Kyriakides","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/practneurol-2015-001311","article-title":"The wrong end of the telescope: neuromuscular mimics of movement disorders (and vice versa)","volume":"16","author":"Bloem","year":"2016","journal-title":"Pract Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/practneurol-2017-001708","article-title":"Metabolic myopathies: a practical approach","volume":"18","author":"Lilleker","year":"2018","journal-title":"Pract Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib11","first-page":"327","article-title":"Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy","volume":"54","author":"Rowe","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2020.101486_bib12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2020.101486_bib13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/mus.880131010","article-title":"Electrophysiological spectrum of inclusion body myositis","volume":"13","author":"Joy","year":"1990","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.berh.2020.101486_bib14","first-page":"565","article-title":"Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease","volume":"266","author":"Breza","year":"2019","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1212\/CON.0000000000000520","article-title":"Peripheral nerve hyperexcitability syndromes","volume":"23","author":"Sawlani","year":"2017","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"11","key":"10.1016\/j.berh.2020.101486_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.nmd.2016.08.014","article-title":"Focal myositis: a review","volume":"26","author":"Devic","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.berh.2020.101486_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2020.101486_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jocn.2008.01.011","article-title":"Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis","volume":"15","author":"Needham","year":"2008","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.berh.2020.101486_bib21","first-page":"CD001555","article-title":"Treatment for inclusion body myositis","volume":"6","author":"Rose","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2020.101486_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.berh.2020.101486_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/mus.25079","article-title":"Development of the sporadic inclusion body myositis physical functioning assessment","volume":"54","author":"DeMuro","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.berh.2020.101486_bib24","doi-asserted-by":"crossref","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.berh.2020.101486_bib25","article-title":"Rapamycin vs. Placebo for the treatment of inclusion body myositis: improvement of the 6 min walking distance, a functional scale, the FVC and muscle quantitative MRI [abstract]","volume":"69","author":"Benveniste","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2020.101486_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2020.101486_bib27","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","article-title":"Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features","volume":"84","author":"Brady","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.berh.2020.101486_bib28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101486_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2019-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101486_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2020.101486_bib31","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2020.101486_bib32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis","volume":"68","author":"Betteridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101486_bib33","first-page":"999","article-title":"A\u00a0longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.berh.2020.101486_bib34","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23291","article-title":"Association of fibrosing myopathy in systemic sclerosis and higher mortality","volume":"69","author":"Paik","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2020.101486_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2020.101486_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2020.101486_bib37","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:09Z","timestamp":1761499149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694220300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1521694220300024"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2020.101486","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pitfalls in the diagnosis of myositis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2020.101486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101486"}}